Burden of Asthma and Role of 2.5 µg Tiotropium Respimat^® as an Add-On Therapy: A Systematic Review of Phase 2/3 Trials.

ABSTRACT:

Introduction

Tiotropium, a long-acting muscarinic antagonist, is approved for maintenance treatment of asthma in patients at least 6 years of age in the USA. We systematically reviewed published evidence on the efficacy and safety of 2.5 µg tiotropium Respimat^® add-on therapy to inhaled corticosteroid (ICS) with or without additional controller medication(s) in children, adolescents, and adults with asthma.

Methods

We searched PubMed from inception until October 3, 2018, for phase 2 and 3 randomized controlled trials (RCTs) evaluating the effects of 2.5 µg tiotropium Respimat^® on lung function parameters in patients with asthma. We extracted adjusted mean differences for lung function data and adverse events (AEs) from relevant articles.

Results

SUBMITTER: Mansfield L 

PROVIDER: S-EPMC6822828 | biostudies-literature | 2019 Oct

REPOSITORIES: biostudies-literature